

AmCad BioMed Corp.

code: 4188

2021 Institutional Investor Conference

Established: 2008

Year of Listing: 2015

Capital: USD18.9M

**CEO
Yili Lee**

Company Introduction



Company Profile




- ▶ Name : AmCad BioMed Corporation
- ▶ Founded : Dec. 2008
- ▶ Capital : TWD 530M
- ▶ Business : Product development, Manufacturing and Sales for Innovative Medical Device
- ▶ President : Yili Lee
- ▶ Location : Taipei City
- ▶ Headcounts : 37

超音波影像AI領航者 安克生醫

Helping physicians diagnose confidently and efficiently.

Roadmap of Medical Innovation Development




Business Model of Innovative Medical Device

BD&L : Business Model



Licensing

License technology to equipment makers and receive licensing fees or royalty.



Distribution




Exclusive or regional rights, single & multi-product deals.



Collaborative Marketing

Collaborate with PACS/AI platforms to market and expand access.

Major Milestones




Product Lines




- FDA 510(k), CE certified
- Automated ultrasound scanning and detection of pharyngeal airway
- Risk evaluation of obstructive sleep apnea (OSA)




- FDA 510(k), CE certified
- Imaging of the backscattered signals for assessment of tissue variation



- FDA 510(k), CE certified
- Differentiation between pulsatile signal and noise




- FDA 510(k), CE, TFDA, CFDA certified
- Assessment of malignancy potential for thyroid nodule sonographic features
- Risk analysis of malignancy for thyroid nodule



- Breast Ultrasound AI Live CAdE/x




- Cytology microscopic image processing
- Visualization and quantification of clinical cytology features



- Point of care ultrasound device
- Real time AI imaging

AmCAD UO[®] Features



10分鐘呼吸中止症檢測系統

- 美國FDA、歐盟CE、台灣TFDA核准
- 專利雷射定位系統
- 自動掃描一致性結果
- 精密上呼吸道分析
- 快速檢測



2021 Operating Updates



2021 Milestones – AmCAD UT[®]

- ▶ Start business in NTUN Health Management Center in Aug. 2021
- ▶ First shipment to Chili Distributor in Jul. 2021
- ▶ Obtained FDA 510 (k) approval of advanced **AmCAD UT[®]** with AI contouring function in Sep. 2021
- ▶ **AmCAD UT[®]** has been used by **244 doctors in 121 hospitals** worldwide. **24 papers & 10 posters** have been published.

ORIGINAL RESEARCH ARTICLE


Front. Endocrinol. | doi: 10.3389/fendo.2021.614630

Risk stratification in patients with follicular neoplasm on cytology: use of quantitative characteristics and sonographic patterns

Provisionally accepted The final, formatted version of the article will be published soon. [Notify me](#)

Ming-Hsun Wu^{1*}, Kuen-Yuan Chen¹, Min-Shu Hsieh¹, Argon Chen^{1*} and Chiung-Nien Chen¹

¹National Taiwan University, Taiwan



可抓到所有惡性，且可讓
47%的良性案例免於開刀

	PPV	NPV	Sensitivity	Specificity	Average*
Sonographic characteristics					
Hypo-echogenicity	0.44 (15/34)	0.77 (24/31)	0.68 (15/22)	0.56 (24/43)	0.62
Calcification	0.48 (12/25)	0.75 (30/40)	0.55 (12/22)	0.70 (30/43)	0.625
Heterogeneous echotexture	0.52 (15/29)	0.81 (29/36)	0.68 (15/22)	0.67 (29/43)	0.675
Blurred margin	0.45 (9/20)	0.71 (32/45)	0.41 (9/22)	0.74 (32/43)	0.575
Irregular margin	0.45 (9/20)	0.71 (32/45)	0.41 (9/22)	0.74 (32/43)	0.6
Taller-than-wide morphology	0.67 (6/9)	0.71 (40/56)	0.27 (6/22)	0.93 (40/43)	0.575
Combination of heterogeneous, irregular margin, and blurred margin	0.49 (22/45)	1.0 (20/20)	1.0 (22/22)	0.47 (20/43)	0.735

CLINICAL ENDOCRINOLOGY

ORIGINAL ARTICLE

Differences in the ultrasonographic appearance of thyroid nodules after radiofrequency ablation

Ming-Hsun Wu, Kuen-Yuan Chen, Argon Chen✉, Chiung-Nien Chen

First published: 03 May 2021 | <https://doi.org/10.1111/cen.14480>

Funding information:

The AmCad BioMed Corporation, Taipei, Taiwan, sponsored this study in terms of technical assistance and financial support

Results

The average volume reduction ratio (VRR) was 74.51% in 1 year (95% confidence interval, 70.63%–78.39%). The only pre-ablation US feature significantly different between nodules with VRR <50% and VRR >50% was the cyst composition (0.05 vs. 0.02, p -value = .02). The VRR and margin change in the first 3 months after ablation were found to be leading indicators significantly correlated to the VRR in 6 months with correlation coefficients (r) = .72 and -.28 (p -value < .0001 and = .0008) and VRR in 1 year with r = .65 and -.17 (p -value < .0001 and = .046), respectively. After RFA, more TNs became ATA high suspicion (2.9% vs. 19.7%, p < .0001) and more appeared to be the non-ATA patterns (12.4% vs. 23.4%, p < .0001). Also, a greater number of post-RFA TNs were classified as ACR-TI-RADS categories 4 and 5 (40.1% vs. 70.1%, p < .0001).

結論：

1. 術前“囊性”的組成較多，可預測結節消融半年後及一年後的效果較佳
2. 三個月後“體積減少”、“邊緣”較術前清楚，可預測結節消融半年後及一年後的效果較佳
3. 消融後，結節超聲特徵會變得更像惡性。

Conclusions

Radiofrequency ablation therapy is effective for treating TNs. Pre-ablation cyst components, 3-month post-ablation volume reduction and margin change of TNs were related to the 6-month and 1-year response. Clinicians should consider that TNs would appear peculiar on US after RFA, mistakenly suggesting malignant potential.

2021 Milestones – AmCAD UO®

- ▶ Start post-market clinical study in NTUH Health Management Center in Aug. 2021.
- ▶ Sign with Distributor in Thailand and secure first overseas PO.
- ▶ Interim study results of trial collaborated with Stanford Sleep Medicine Center published at 2021APSS
- ▶ Conducted corporate employee OSA detection events in Acer and AU Optronics Corp.

Stanford Clinical Study Publication

-- 2021 APSS Poster Publication

An AI-Based Ultrasound Scanning Protocol for the Airway in Obstructive Sleep Apnea



Stanley Y. Liu, M.D., D.D.S., FACS¹, Valerie Garcia, B.A.¹, Argon Chen, Ph.D.², Yili Li, M.B.A.³, Clete A. Kushida, M.D., Ph.D.¹

1. School of Medicine, Stanford University, 2. College of Engineering, National Taiwan University, 3. AmCAD BioMed

Abstract

Introduction

Visualization of the upper airway in obstructive sleep apnea (OSA) diagnosis for improved treatment outcome remains challenging.

Nasopharyngoscopy (NPI) is an integral part of the upper airway examination that is usually performed by otolaryngologists. It allows identification of tonsillar hypertrophy and simulation of airway collapsibility with Muller's Maneuver (MM). Nevertheless, it is user-dependent, invasive, costly, and does not allow quantitative measures.

We present the use of an ultrasound scanning protocol based on an artificial intelligence algorithm (AI-U) for visualization of the upper airway.

Study Design

Consecutive adult subjects with OSA over the age of 18 presenting to the Stanford sleep surgery clinic from July 2020 to May 2021 were considered for the study (IRB 53172).

Exclusion criteria include: 1. unwillingness to give informed consent, 2. incapable of performing MM, 3. history of nose, throat, or neck surgery, 4. diagnosis of congestive heart failure, chronic pulmonary disease, 5. co-morbid sleep disorders, 6. pregnancy.

A total of 51 subjects (72.6% male, median Age/BMI: 13/38/25.2) are included in the current analysis.

OSA was confirmed via attended or home polysomnography. NP and AI-U were performed to evaluate airway collapsibility at the soft palate (PAL), lateral pharyngeal wall (LPW), base of the tongue (BOT), and epiglottis (E, AI-U only).

NP was performed by qualified examiners with MM rated per routine clinical examination.

Methodology

Laser beams were used to align subject position to the sagittal plane, the Frankfort horizontal plane (FH plane) and a cross-section plane through the Hyoid bone and the external acoustic Meatus (HM plane). The head and neck of the subject in supine position were then positioned to the center with the FH plane perpendicular to the horizon with the ultrasound transducer aligned with the laser projection of the HM plane. (Figure 1). A 3D-degree ultrasound scan was performed on the awake subject to acquire sequential images of the pharynx. The images were divided into four parts (Figure 2).




Figure 1: Laser alignment to standardize head and neck position




Figure 2: Ultrasound scan of pharyngeal airway: Soft palate (PAL), Lateral pharyngeal wall (LPW), Base of the tongue (BOT), and Epiglottis (E).

Three replicates of sector-scans were performed per subject under tidal breathing and MM. Analyses of the US and tissue widths were conducted on the transverse view of the submental ultrasound (US) images by an FDA-cleared software AmCAD-UO (K160607). Regions of interest include 1) airway space (yellow) and 2) tissue surrounded the airway (green). The airway space, represented as hypercholeic points in US image, is highlighted by red dots (Figure 3). The change in the airway and tissue width were then calculated by:

$$\text{Change in width} = \frac{\text{Tidal-breathing width} - \text{MM width}}{\text{Tidal-breathing width}} \times 100\%$$

Statistical relationships among the features obtained from US images, NP, and AHI (excluding the outliers) were performed using two-tailed t-tests.



Figure 3: AmCAD-UO user interface for upper airway evaluation

Results

1. Significant correlation was found between AHI and NP collapsibility at the LPW ($p < 0.001$) (Figure 4).




Figure 4: Correlation between AHI and LPW collapsibility

2. US shows significant correlations with NP and AHI at the PAL, LPW, and BOT. US features include airway space changes and airway muscle contraction (Figure 5, Table 1).




Figure 5: Correlations between airspace and muscle contraction from US images with NP and AHI.

Table 1: Correlations between AHI and changes in muscle contraction

	O	T	E
AHI	$r = 0.35$ $P = 0.012$	$r = 0.34$ $P = 0.016$	$r = 0.33$ $P = 0.019$

Conclusion

Visualization of upper airway collapsibility remains an important but difficult task in OSA. Nasopharyngoscopy is invasive, expensive, and user-dependent without the quantitative measures. Our AI-based ultrasound scanning protocol addresses both the limitation of nasopharyngoscopy and a key need for practitioners across disciplines to improve collaborative care.

Protocol design:

- PSG (Gold Standard)
- Endoscopy (Awake or Drug Induced)
- AmCAD UO

Results:

- ✓ Significant correlation was found between AHI and NP collapsibility at the LPW
- ✓ Significant correlation was found between UO and NP, as well as UO and AHI at the PAL, LPW, and BOT

Special Lecture on TSSM & 1st OSAsia

19th TSSM & 1st OSAsia Mar. 27-28, 2021

19th TSSM & 1st OSAsia

Saturday, Mar. 27, 2021

Rm. 2

Speaker: Chae-Seo Rhee (Korea)

S04-4

Maxillary expansion with different appliances for different dental occlusion can help POSA treatment

Speaker: Je-Yang Jau 趙哲陽 (Taiwan)

14:30-15:00

Special Lecture 02

Ultrasonic Assessment for OSA

Moderator: Hsueh-Yu Li 李學禹 (Taiwan) & Li-Ang Lee 李立昂 (Taiwan)

SL02-1

Upper Airway Ultrasonic Assessment for OSA Diagnosis and Treatment

Speaker: Argon Chen 陳正剛 (Taiwan)

15:00-16:00

Symposium 06

Inner Ear and OSA

Moderator: Shih-Chieh Shen 沈士傑 (Taiwan)

S06-1

Effects of sleep apnea on inner ear diseases and tinnitus.

Speaker: Juen-Haur Hwang 黃俊豪 (Taiwan)

S06-2

How do OSA influence inner ear connecting with brain? (vertigo)

Speaker: Meiho Nakayama (Japan)

S06-3

Idiopathic Sudden Sensorineural Hearing Loss in Patients with Obstructive Sleep Apnea: A Retrospective Case-Control Study

Speaker: Shih-Chieh Shen 沈士傑 (Taiwan)

16:00-17:00

Symposium 08

Application of Ultra-sound in OSA

Moderator: Jeng-Wen Chen 陳正文 (Taiwan)

Special Lecture

SL02_Special Lecture 02

Date: Mar. 27 Time: 14:30-15:00



SL02-1

陳正剛 Argon Chen

Country:

Taiwan

Organization:

National Taiwan University

Education Background:

Ph.D. in Industrial Engineering, Rutgers University

M.S. in Statistics, Rutgers University

M.S. in Industrial Engineering, Rutgers University

Specialized Field:

CADe/CADx, Medical Data Mining, Automatic Intelligence, Applied Statistics



19th Virtual Annual Meeting of Taiwan Society of Sleep Medicine
in Conjunction with 1st OSAsia (Asia Obstructive Sleep Apnea)

Special Lecture

SL02_Special Lecture 02 Date: Mar. 27 Time: 14:30-15:00

SL02-1

Upper Airway Ultrasonic Assessment for OSA Diagnosis and Treatment

陳正剛 Argon Chen (Taiwan)

National Taiwan University

It has been reported that changes in diameter of the pharyngeal airway observed by medical imaging are associated with obstructive sleep apnea (OSA). Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) are both useful for evaluation of various anatomical planes that might be the site of obstruction. However, MRI and CT cannot be widely applied to diagnosis of OSA due to the high costs and radiation exposure in case of CT scan. In contrast, ultrasound imaging of the upper airway state is radiation-free, less costly, real time, and portable, thus allowing for high accessibility for assessment of OSA.

Air is a type of substances poor in conducting the ultrasound wave. When the ultrasound beam reaches the interface between tissue and air, almost all the ultrasound energy is echoed. Therefore, when the airspace is encountered, hyperechoic signals can be observed. Such sonographic characteristics can be then used for analysis of the upper airway state. However, the airspace is sometimes not observable in ultrasound imaging due to the anteroposterior collapse or lateral contraction of soft tissue caused by the gravitational effect on the subjects in supine position or by certain breathing maneuvers, such as Müller's maneuver, performed by the subjects. This research aims to study how the observabilities and diameter changes, if observable, of different pharyngeal airway segments are related to the OSA severity and treatment interference.



安克生醫股份有限公司
AmCad BioMed Corporation

AmCAD UO® Press Coverage

www.mta-dialog.de | www.dvta.de

MTA Dialog

Die Fachzeitschrift

66 | MTA INTERN | Aus der Industrie

Diagnose von Schlafapnoe

Die AmCad BioMed Corporation, ein Unternehmen aus Taiwan, präsentiert das neuartige Diagnosesystem AmCAD-UO zur schnellen Erkennung des obstruktiven Schlafapnoe-Syndroms (OSAS) in Deutschland. Innerhalb von nur zehn Minuten soll das AmCAD-UO-System mit der lasergesteuerten Positionierung die oberen Atemwege präzise und zuverlässig scannen – und das am wachen Patienten. Das Gerät soll die Ultraschallbilder mithilfe künstlicher Intelligenz (KI) analysieren und rekonstruieren. Damit vergleicht es automatisch die Zustände der Atemwege zwischen normaler Atmung und dem Müller-Manöver-Modell, einer Atmungsmethode, die Schnarchen nachahmt, so das Unternehmen. „Das AmCAD-UO bietet eine zuverlässige Risikobewertung für Patienten mit sowohl moderatem als auch schwerem OSAS“, erläutert Yili Lee, Präsidentin von AmCad BioMed. „Mit unserer einfachen und schnellen OSAS-Diagnose im wachen Zustand unterstützen wir Schlafmediziner zudem, die Ursachen bei blockierten Atemwegen zu identifizieren.“ Der Einsatz des AmCAD-UO ist wesentlich kostengünstiger als herkömmliche Diagnosemethoden und entlastet gleichzeitig die Schlafzentren. Das AmCAD-UO-System erhält das CE-Kennzeichen der EU und die Zulassungen von der Taiwan Food and Drug Administration (TFDA) und der US Food and Drug Administration (FDA). Seit Ende 2020 führt das Stanford Sleep Medicine Center gemeinsam mit AmCad BioMed eine klinische Studie zum AmCAD-UO durch. Erhältlich ist das Diagnosesystem in Deutschland seit 1. Juni 2021.

Weitere Informationen unter <https://www.amcad.com.tw/en>

Systeme zur His-Bündel-Stimulation



Selecta 3D Katheter, Sofia 5 e Biotronik

Die Biotronik hat kürzlich sein neues Instrumentarium zur Unterstützung von Conduction System Pacing (CSP)-Prozeduren vorgestellt. Bei der Entwicklung des Selecta-3D-Katheters hat Biotronik nach eigenen Angaben ein mit spezialisierten klinischen Experten zusammengearbeitet. Der Katheter ist in neun Längen- und Krümmungsvarianten verfügbar und ist im CE-Raum für den Einsatz bei His-Bündel-Prozeduren zugelassen. Er sei für die Elektrodenplatzierung in Atrium oder Ventrikel ausgelegt und eigne sich für Prozeduren zur Stimulation des Reizleitungssystems. Selecta 3D unterscheide sich von anderen Produkten auf dem Markt durch eine größere Stabilität. Der Katheter behalte auch bei potentiell länger dauernden CSP-Prozeduren seine Form bei, betont der Hersteller. Angesichts vielfältiger Patientenanatomien sei für eine Steigerung der Erfolgsrate bei diesen Prozeduren eine bessere Auswahl an Tools zur His-Bündel-Stimulation nötig. Die größere Variationsvielfalt bei Selecta-3D-Kathetern für unterschiedliche Patientenanatomien gebe Ärzten mehr Kontrolle und Flexibilität bei den Eingriffen. Für den führenden CSP-Experten Dr. Francesco Zanon vom Universitätsklinikum „Santa Maria della Misericordia“ in Italien ist eine breitere Katheterauswahl entscheidend für positive Ergebnisse. Die größte Herausforderung bei Eingriffen zur Stimulation des Reizleitungssystems ist die Auswahl passender Tools für die gegebenen Patientenanatomien. Die passende Katheterkrümmung ist der Schlüssel zum Erfolg. Mit der historischen Entwicklung der His-Bündel-Tools haben wir eine lange Lernphase durchlaufen. Die Neuerungen beim Selecta 3D werden mehr Ärzten erfolgreiche Eingriffe

DVTA

Dachverband für Technologie-innen- und -anlagen/-systeme in der Medizin Deutschland e.V.



AmCAD-UO diagnostiziert Schlafapnoe mit KI.

© AmCad BioMed

SCHLAU NEWS

NEWS AUS ALLER WELT - INFO, TIPPS, TRICKS...

Online Zeitung

POLITIK :: WIRTSCHAFT :: NETZNEWS :: FREIZEIT :: BILDUNG ::

Willkommen bei Online Zeitung, dem Portal für Pressemitteilungen aus Deutsch-

Diagnose von Schlafapnoe innerhalb 10 Minuten

Mai 05 18:30 2021



AmCAD-UO diagnostiziert Schlafapnoe innerhalb von 10 Minuten mit künstlicher Intelligenz

Neuartiges Diagnosesystem AmCAD-UO Wachzustand mithilfe künstlicher Intelligenz Corporation – innovativer Medizintechnik – präsentiert das neuartige Diagnosesystem zur schnellen Erkennung des obstruktiven (OSAS) jetzt in Deutschland. Innerhalb von nur zehn Minuten scannt das AmCAD-UO-System mit Positionierung die oberen Atemwege präzise und das am wachen Patienten. Das rekonstruiert die Ultraschallbilder mithilfe (KI). Damit vergleicht es automatisch

Atemwege zwischen normaler Atmung und dem Müller-Manöver-Modell, einer Atmungsmethode, die Schnarchen nachahmt. „Das AmCAD-UO bietet eine zuverlässige Risikobewertung für Patienten mit sowohl moderatem als auch schwerem OSAS“, erläutert Yili Lee, Präsidentin von AmCad BioMed. „Mit unserer einfachen Diagnose im wachen Zustand unterstützen wir Schlafmediziner zudem, die Ursachen bei blockierten Atemwegen zu identifizieren.“ Der Einsatz des AmCAD-UO ist wesentlich kostengünstiger als herkömmliche Diagnosemethoden und entlastet gleichzeitig die Schlafzentren.

Positionierung der oberen Atemwege präzise und zuverlässig – und das am wachen Patienten. Das Gerät analysiert und rekonstruiert die

Weltjournal

Dienstag, Juli 13, 2021

Presseverteiler Kontakt



Medizin, Gesundheit und Wellness

Diagnose von Schlafapnoe innerhalb 10 Minuten

15. Mai 2021

AmCad BioMed AmCAD-UO CPAP Herz-Kreislauf Herzinfarkt Obstruktive Schlafapnoe OSAS Schlaf Schlafapnoe Schlafapnoe Schnarchen Taitra Taiwan Excellence

Neuartiges Diagnosesystem AmCAD-UO erkennt OSAS im Wachzustand mithilfe künstlicher Intelligenz

Die AmCad BioMed Corporation – innovativer Medizintechnik-Spezialist aus Taiwan – präsentiert das neuartige Diagnosesystem AmCAD-UO zur schnellen Erkennung des obstruktiven Schlafapnoe-Syndroms (OSAS) jetzt in Deutschland. Innerhalb von nur zehn Minuten scannt das AmCAD-UO-System mit der lasergesteuerten Positionierung die oberen Atemwege präzise und zuverlässig – und das am wachen Patienten. Das Gerät analysiert und rekonstruiert die Ultraschallbilder mithilfe künstlicher Intelligenz (KI). Damit vergleicht es automatisch die Zustände der Atemwege zwischen normaler Atmung und dem Müller-Manöver-Modell, einer Atmungsmethode, die Schnarchen nachahmt. „Das AmCAD-UO bietet eine zuverlässige Risikobewertung für Patienten mit sowohl moderatem als auch schwerem OSAS“, erläutert Yili Lee, Präsidentin von AmCad BioMed. „Mit unserer einfachen und schnellen OSAS-Diagnose im wachen Zustand unterstützen wir Schlafmediziner zudem, die Ursachen bei blockierten Atemwegen zu identifizieren.“ Der Einsatz des AmCAD-UO ist wesentlich kostengünstiger als herkömmliche Diagnosemethoden und entlastet gleichzeitig die Schlafzentren.

Effektive OSAS-Diagnose und Therapiebegleitung



安克生醫股份有限公司
AmCad BioMed Corporation

AmCAD UO[®] Marketing Promotions

哈佛健檢進駐洽談



CPAP廠商合作洽談



PEX

雅博



ResMed

AmCAD UO[®] in NTUH HMC



安裝前



AmCAD UO[®] Marketing Promotions

身心健康關懷講座第45講

沉默殺手 睡眠呼吸中止症

您會打呼嗎？您常被家人如雷的鼾聲影響睡眠嗎？

在台灣，有40萬以上的人罹患睡眠呼吸中止症，但因多都在睡著時發生，且無其他特別症狀，所以須靠醫師及家屬提高警覺才能發現。

睡眠呼吸中止症影響睡眠品質，易造成白天嗜睡、頭痛、注意力記憶力下降、高血壓、心肌梗塞、中風等心血管病，引起糖尿病、性功能障礙等泌尿科問題，甚至有猝死的危險性。

希望貴會能一起來了解睡眠呼吸中止症，為自己及家人的健康建立多一道安全防線！

3/12 (Fri.)
12:10-13:30
宏碁大樓25樓附梯教室

陳淳宏 醫師
長庚醫院睡眠中心
亞洲睡眠醫學學會理事長

報名方式：即日起至3/8(一)18:00止，請至Acer Family APP報名。

其他說明：1. 本講座開放Teams觀聽，請於報名時選擇參加方式。
2. 講座時間為90分鐘，為尊重講師，請盡量全程參與活動。
3. 本堂聯絡人：KAS0207 Alice Wang (#2237)


參加本場講座之同仁，將有機會報名由宏碁生醫提供的 免費睡眠呼吸中止檢測 (3/23(二)) @宏碁大樓7樓，檢測時間約10-15分鐘，歡迎有需求的同仁踴躍參加！

Employee Relationship
— Acer Family —



2021 ECR Online Exhibition

ECR 2021



AmCAD - UT®
Detection

ULTRASOUND CAD
FOR THYROID NODULE

- Visualization and quantification of sonographic features
- Recommendation based on TI-RADS and global guidelines
- Automated report generation

**ULTRASOUND BASED DETECTION FOR
OBSTRUCTIVE SLEEP APNEA (AmCAD-UO)**

IN 10 MINUTES
FOR AWAKE PATIENTS

- Laser-Guided Positioning and Automated Scanning
- Automated Upper Airway Ultrasound Scanning
- Real-time Detection and Analysis of Pharyngeal Airway
- Risk Evaluation of Obstructive Sleep Apnea
- 3D Ultrasound image Reconstruction

Show content ▼



Product Development




AmCAD US[®] – on Fatty Liver Detection

- ▶ Global Liver Disease Diagnostics Market Value EST :
US\$ **48.7B** by 2027; US\$31.2B in 2020; CAGR **6.5%** (2020~2027)
(from Grand View Research)
- ▶ AmCAD-US is a software device intended to visualize and analyze the statistical distributions of backscattered signals echoed by tissue compositions in the body. The information obtained from analysis may be used in tissue characterization and is shown effective **in analysis of hepatic steatosis grades**.
- ▶ FDA 510(k) application has been filed.

Dense Breast issue

Dense Breast Tissue Categories:

(A) Fatty; (B) Scattered fibroglandular density; (C) Heterogeneously dense; (D) Extremely dense



How do you answer the question "Are you dense?" Breasts which are (C) heterogeneously dense, or (D) extremely dense on mammography, are considered "dense breasts"



► Women with Dense Breasts :

- 70-80% of women in Asia
- 40-50% of women in the US.
- 4~6X more likely to get breast cancer


- Sensitivity of mammogram significantly decrease to 48.6% for Dense Breasts compared to 88.9% for fatty breasts.
- FDA proposed New Mammogram Guidelines for Dense Breasts on Mar 27, 2019
 - To notify and educate women with dense breasts about increased cancer risk and imprecise mammograms.
 - Breast Ultrasound is recommended as a priority supplemental detection because its cost-effectiveness.

AmCAD UB[®] Market Strategy

- ▶ After New Mammogram guideline for Dense Breasts proposed by FDA in Mar. 2019:
 - Hologic acquired Supersonic in Aug.2019.
 - Fujifilm announced to acquire Hitachi (diagnostic imaging BU) in Dec. 2019.
- ▶ Dense Breast Issue has become the key driver of growth for ultrasound market。
- ▶ AmCAD UB (Breast Ultrasound Real-time CAdE/x) is going to be integrated into an ultrasound system, therefore, we are in the process of searching for collaboration partnerships (ex. licensing or co-development) with global ultrasound companies, such as GE, Philips, Siemens、Fujifilm、Cannon、SuperSonic...etc.

Global Breast Imaging Market Size worth \$7.3 B By 2024 with 12.2% CAGR

- 71% --Mammography + Ultrasound
- 10% --MRI



Financials



Consolidated Balance Sheet

單位：新台幣仟元

科 目	110.6.30	%	109.12.31	%
Current Assets	426,419	66	422,117	64
Non-current Assets	222,201	34	234,430	36
Total Assets	648,620	100	656,547	100
Current Liabilities	44,675	7	47,713	7
Non-current Liabilities	19,372	3	13,730	2
Total Liabilities	64,047	10	61,443	9
Capital	532,214	82	532,214	81
Additional Paid-in Capital	94,524	14	94,377	14
Accumulated Deficit	(132,374)	(20)	(117,864)	(18)
Other Equity	(4,747)	(1)	(11,024)	(1)
Parent Equity	489,617	75	497,703	76
Minority Interest	94,956	15	97,401	15
Total Equity	584,573	90	595,104	91
Total Liabilities and Equity	648,620	100	656,547	100

Consolidated Income Statement

Unit : K TWD

Items	2021H1		2020H1		YoY
	AMT	%	AMT	%	%
Sales Revenue	31,693	100	29,468	100	8%
Gross Margin	20,892	66	19,481	66	7%
Operating Expenses	(45,224)	(142)	(50,085)	(170)	-10%
Operating Loss	(24,332)	(76)	(30,604)	(104)	-20%
Non-operating Gain	2,536	8	4,379	15	-42%
Net Loss	(21,796)	(68)	(26,225)	(89)	-17%
Net Loss – Parent	(19,351)	(61)	(21,285)	(72)	-9%
Net Loss – Minority	(2,445)	(8)	(4,940)	(17)	-51%
EPS (TWD)	(0.36)		(0.40)		

Future Outlook – AmCAD UT[®]、AmCAD UO[®]

► Domestic Market :

- ✓ **AmCAD UT[®]** targets health check in hospitals and health check center channels with **subscription business model** ;
- ✓ **AmCAD UO[®]** also targets **health check center channels** with rental as main business model

► Global Market :

- ✓ Expanding global distribution channels by A. participating on-line and off-line exhibitions, B. more publications on academic medical journals and medical seminars, C. support local clinical studies for market promotion
- ✓ Searching for licensing deal with global ultrasound companies for AmCAD UT.

Future Outlook – International Expo.

Medica 2021 Nov.



Leading International Trade Fair
DÜSSELDORF, GERMANY
15-18 NOVEMBER 2021
Member of MEDICA Alliance

World Forum for Medicine
www.medica.de

Home Magazine Companies & Products Forums & Conferences Visitors Exhibitors Press
Contact, Traveling & Hotels

MEDICA 2021– Top in all medical areas
The world of medicine meets at MEDICA 2021.
A must for anyone who wants to experience tomorrow's healthcare market live.



Apply online now as an exhibitor of MEDICA 2021 in Düsseldorf / Germany

Be part of the No. 1 Register conveniently and early online in just a few steps. For exhibitors 2020, the registration forms are already personalized.

NEW Registration deadline / beginning of hall layout planning was 01 May 2021.

Media Partner
EUROPEAN HOSPITAL

World Sleep 2022 Mar.

March 11-16
2022
WORLD SLEEP
Rome • Italy

RSNA 2021 Dec.



RSNA
Radiological Society of North America


Membership Annual Meeting Journals Education Research Practice Tools COVID-19

RSNA 2021
REDEFINING RADIOLOGY
November 28 to December 2

Save the date: RSNA 2021
Join us in Chicago for our 107th Scientific Assembly and Annual Meeting, November 28 to December 2, McCormick Place.

Annual Meeting

Medical Fair Asia 2022 Aug.



31 AUG – 2 SEP 2022 | MARINA BAY SANDS, SINGAPORE 343 DAYS 02 HOURS 46 MINS

MEDICAL FAIR ASIA
14th International Exhibition on Hospital, Diagnostic, Pharmaceutical, Medical & Rehabilitation Equipment & Supplies

ABOUT EXHIBITOR LIST EXHIBIT VISIT MEDIA

Home / About / Show Info

SHOW INFO

With a well-established history since 1997, the 14th edition of **MEDICAL FAIR ASIA 2022** is set to take place from **31 August – 2 September 2022**. Focusing on Hospital, Diagnostics, Pharmaceutical, Medical & Rehabilitation Equipment & Supplies, the leading medical and healthcare exhibition will continue to feature the latest medical technology and innovations, and healthcare equipment and supplies, to provide the industry a platform with the best business opportunities to navigate the dynamic marketplace in this region.

MEDICAL FAIR ASIA is organised by Messe Düsseldorf Asia a subsidiary of Messe Düsseldorf GmbH based in Germany and organiser of the world's no. 1 medical exhibition – MEDICA. The exhibition is also a member of the MEDICA Alliance, the global network for medical trade fairs worldwide.


WHY ASIA?

Three photographs showing people at the Medical Fair Asia 2022 exhibition.

Future Outlook – Product Development


- ▶ **AmCAD US®** for Fatty Liver Detection
- ▶ **AmCAD UB® AI Live** Breast ultrasound real-time CAdE/x

These two products will be integrated into ultrasound system. Other than existing compatible ultrasound, we are in the process of searching for more collaboration partnerships (ex. licensing or co-development) with other ultrasound companies.



Future Outlook


- ▶ There have been more cases of partnerships between medical images AI companies and ultrasound companies. For example, this Aug. Caption Health (AI-guided ultrasound software) and Butterfly Network (handheld ultrasound manufacturer) announced strategic partnership.



Caption Health + Butterfly
Strategic Partnership



- ▶ AmCad as a pioneer ultrasound AI company with multiple FDA approved products, shall be a preferred option for strategic partnership to ultrasound companies.



SIEMENS

Canon



FUJIFILM
Value from Innovation

Q & A